Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Heyckendorf

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Respiration; International Review of Thoracic Diseases|September 6, 2016
Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary AspergillosisHelmut J F Salzer, Nasstasja Wassilew, Niklas Köhler, et al.
Frontiers in Immunology|October 31, 2022
Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infectionNathalie Rohmann, Paula Stürmer, Corinna Geisler, et al.
Plos One|September 4, 2014
Development of a one-step probe based molecular assay for rapid immunodiagnosis of infection with M. tuberculosis using dried blood spotsThomas Blauenfeldt, Jan Heyckendorf, Sidse Graff Jensen, et al.
Frontiers in Immunology|June 29, 2026
PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapyJohanna Eggeling, Martina Sester, Christoph Lange, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 27, 2015
T-Cell Therapy: Options for Infectious DiseasesShreemanta K Parida, Thomas Poiret, Liu Zhenjiang, et al.
Tuberculosis (Edinburgh, Scotland)|May 10, 2016
Thermostability of IFN-γ and IP-10 release assays for latent infection with Mycobacterium tuberculosis: A TBnet studyThomas Blauenfeldt, Dirk Wagner, Martine Aabye, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2017
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant TuberculosisJan Heyckendorf, Sönke Andres, Claudio U Köser, et al.
Med (New York, N.Y.)|October 25, 2021
Tuberculosis endotypes to guide stratified host-directed therapyAndrew R DiNardo, Tomoki Nishiguchi, Sandra L Grimm, et al.
Pathogens & Immunity|June 28, 2024
A Transcriptomic Biomarker Predicting Linezolid-Associated Neuropathy During Treatment of Drug-Resistant TuberculosisNika Zielinski, Dragos Baiceanu, Antonela Dragomir, et al.
The Lancet. Microbe|May 12, 2024
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profilesStephen H Gillespie, Andrew R DiNardo, Sophia B Georghiou, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Respiration; International Review of Thoracic Diseases|September 6, 2016
Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary AspergillosisHelmut J F Salzer, Nasstasja Wassilew, Niklas Köhler, et al.
Frontiers in Immunology|October 31, 2022
Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infectionNathalie Rohmann, Paula Stürmer, Corinna Geisler, et al.
Plos One|September 4, 2014
Development of a one-step probe based molecular assay for rapid immunodiagnosis of infection with M. tuberculosis using dried blood spotsThomas Blauenfeldt, Jan Heyckendorf, Sidse Graff Jensen, et al.
Frontiers in Immunology|June 29, 2026
PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapyJohanna Eggeling, Martina Sester, Christoph Lange, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 27, 2015
T-Cell Therapy: Options for Infectious DiseasesShreemanta K Parida, Thomas Poiret, Liu Zhenjiang, et al.
Tuberculosis (Edinburgh, Scotland)|May 10, 2016
Thermostability of IFN-γ and IP-10 release assays for latent infection with Mycobacterium tuberculosis: A TBnet studyThomas Blauenfeldt, Dirk Wagner, Martine Aabye, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2017
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant TuberculosisJan Heyckendorf, Sönke Andres, Claudio U Köser, et al.
Med (New York, N.Y.)|October 25, 2021
Tuberculosis endotypes to guide stratified host-directed therapyAndrew R DiNardo, Tomoki Nishiguchi, Sandra L Grimm, et al.
Pathogens & Immunity|June 28, 2024
A Transcriptomic Biomarker Predicting Linezolid-Associated Neuropathy During Treatment of Drug-Resistant TuberculosisNika Zielinski, Dragos Baiceanu, Antonela Dragomir, et al.
The Lancet. Microbe|May 12, 2024
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profilesStephen H Gillespie, Andrew R DiNardo, Sophia B Georghiou, et al.
Pageof 7